Featured news from NHIVNA

HIV-related news from NAM

Studies continued to support tenofovir alafenamide combination pill as it nears US approval
Liz Highleyman, 2015-10-19 08:10:00

A single-tablet regimen containing a new formulation of tenofovir maintained viral suppression for people switching from other combinations and was associated with improved kidney function and bone health, according to studies presented at IDWeek 2015 last week in San Diego. Other research showed that the new formulation works better than the old one for black people and for older people, and that it can be safely used with sofosbuvir/ledipasvir (Harvoni) for hepatitis C treatment.

Gilead Sciences’ tenofovir alafenamide, or TAF, is a new pro-drug formulation that delivers the active agent to HIV-infected cells more efficiently than the current tenofovir disoproxil fumarate, or TDF (Viread, also in Truvada, Atripla, Eviplera and Stribild). TAF produces adequate intracellular drug levels with smaller doses, which means lower concentrations in the blood and less drug exposure for the kidneys, bones, and other organs and tissues.